Our corporate headquarters are located in Montrouge, France.
−Removed: Our principal offices occupy a 4,470 square meter facility consisting of
−Removed: office and laboratory space, pursuant to a lease agreement dated March 3, 2015, which expires on March 8, 2024.
−Removed: We entered into an additional lease for offices in Montrouge, France in July 2018.
−Removed: This facility consists of 1,808 square
−Removed: meters of office space, pursuant to a lease agreement dated July 1, 2018, which initially expires on June 30, 2027.
−Removed: In December 2020, in light of our global restructuring, we notified the landlord of our intention to terminate the lease
−Removed: for the additional office space as of June 30, 2021.
−Removed: We also have two facilities in Bagneux, France.
−Removed: These facilities consist of 2,237 square meters of office
−Removed: and laboratory space and are used primarily by our industrial and production teams.
−Removed: One of the facilities is our pharmaceutical manufacturing establishment, which is focused on the quality control of our manufactured therapeutic patches.
−Removed: 2018, we entered into an addendum to our lease for an additional 500 square meters of office space in building B of Green Square, Bagneux, France.
−Removed: These facilities are leased under one agreement, which initially expires on May 31, 2030.
−Removed: December 2020, we notified the landlord of our intention to terminate the lease agreement for both spaces as of August 31, 2021.
−Removed: We also have facilities
−Removed: in North America that were initially intended to support our U.S.
+Added: Our principal offices occupy a 4,470 square meter facility, pursuant to a lease agreement dated March 3, 2015 which expires March 8, 2024.
+Added: Our primary U.S.
+Added: office is located in Summit, New Jersey.
+Added: In September 2016, we entered into a lease for a commercial facility of 8,919 square feet in Summit, New Jersey, which was intended to support the launch and commercialization of Viaskin Peanut in North America, if the appropriate regulatory approvals were received.
+Added: In July 2018, we entered into a lease for an additional 12,629 square feet in the same building and made both leases co-terminus on July 10, 2028.
+Added: This lease included extension options of two five-year periods.
+Added: In light of our global restructuring and the current stage of regulatory interactions regarding Viaskin Peanut, the company entered into a termination agreement for its U.S.
+Added: The agreement provided for the termination of the lease effective on January 31, 2022, in exchange for a one-time lump sum early termination fee.
+Added: We also have facilities in North America that were initially intended to support our U.S.
subsidiary as well as future commercialization needs.
We lease 3,780 square feet of office space in Tower 49, New York, New York.
−Removed: This lease is for a period of 65 months and expires
−Removed: on February 25, 2023.
−Removed: In light of our global restructuring, the current stage of regulatory interactions regarding Viaskin Peanut, and the ongoing COVID-19 pandemic, we are currently seeking to sublease
−Removed: this office space, subject to landlord consent.
−Removed: In September 2016, we entered into a lease for a commercial facility of 8,919 square feet in Summit, New
−Removed: Jersey, which is intended to support the launch and commercialization of Viaskin Peanut in North America, if the
−Removed: appropriate regulatory approvals are
−Removed: In July 2018, we entered into a lease for an additional 12,629 square feet in the same building and made both leases co-terminus on July 10, 2028.
−Removed: This lease includes extension options of two
−Removed: five-year periods.
−Removed: In light of our global restructuring and the current stage of regulatory interactions regarding Viaskin Peanut, we are currently seeking to sublease the additional 12,629 square feet, subject to landlord consent.
−Removed: We believe that our office, laboratory, and commercial spaces are sufficient to meet our current needs and that suitable additional space will be available
−Removed: if, as and when needed.
+Added: This lease is for a period of 65 months and expires on February 25, 2023.
+Added: In light of our global restructuring, the current stage of regulatory interactions regarding Viaskin Peanut, and the ongoing COVID-19 pandemic, we entered into a sublease agreement of this office space in June 2021.
+Added: We consider our facilities to be suitable and adequate for the management and operation of our business.
+Added: We believe that suitable additional or alternative space will be available to accommodate our future growth.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.